2 results
Approved WMOCompleted
Primary: to assess the effect of intravenous (IV) ozanezumab (15 mg/kg once every 2 weeks) compared to placebo on the physical function and survival of ALS patients over a treatment period of 48-weeks.Secondary (major): other clinical outcomes,…
Approved WMOCompleted
Primary:To evaluate the clinical efficacy of nemiralisib compared with placebo to reduce the annual rate of moderate and severe exacerbations in participants with COPD.Secondary:Further efficacy parameters pertaining to exacerbations and aligned…